Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TAS-116 in advanced solid tumors
NCT02965885Phase 1Completed
- Sponsor
- Taiho Oncology
- Start
- Jul 2017
- Primary completion
- May 2019
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 1, open-label, single-arm trial of pimitespib in solid tumor (advanced stage), breast cancer and non-small cell lung cancer (NSCLC), sponsored by Taiho Oncology. Primary endpoints: Dose Limiting Toxicity at 21 days, Treatment-Emergent Adverse Events and 1 more. Started Jul 2017; status: completed.
02
Drugs
pimitespib
03
Conditions
solid tumor (advanced stage)breast cancernon-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT02965885.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02965885.